Find Clinical Trials & Studies

Casdatifan and Cabozantinib vs Placebo and Cabozantinib in Patients with ccRCC

I'm Interested!
Please call
1-866-373-1464

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Sex: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase I
  • Conditions Being Studied: Cancer - Kidney

Study Purpose

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the most recent regimen (either adjuvant monotherapy or first-line in combination with anti-CTLA-4 or VEGFR-TKI), with no more than 1 prior regimen in the metastatic setting.

Principal Investigator
Pedro Barata MD
Department/Division
Cancer (Thoracic)
  • UH IRB: 25-649;STUDY20251367 / Pro00091046
  • StudyID: ARCS1825
  • ClinicalTrials.gov: NCT07011719
I'm Interested!
Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL

Cancer Trials: 1-866-373-1464